Analytical Data
-
Gene name
FGF-21
- Application
-
Alternative Names
/
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NSA1
-
Expression Region
29-209aa
-
Molecular Weight
23.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast growth factor 21 (FGF-21) is a metabolic regulator primarily produced by the liver, adipose tissue, and skeletal muscle, playing a crucial role in glucose and lipid metabolism, as well as in energy homeostasis. Its potential as a therapeutic agent has garnered significant attention due to its ability to improve insulin sensitivity, promote weight loss, and exert anti-diabetic effects. In various preclinical and clinical studies, FGF-21 has been shown to influence various metabolic pathways, making it a candidate for the treatment of obesity, Type 2 diabetes, and related metabolic disorders. The recombinant protein form of FGF-21 has been engineered to enhance its stability and bioavailability, allowing for more effective therapeutic application. Research has focused on elucidating its mechanisms of action, optimizing its pharmacokinetics, and assessing safety profiles in animal models and human trials. Current investigations are exploring the efficacy of FGF-21 in conjunction with other metabolic interventions, aiming for a comprehensive understanding of its therapeutic potential while addressing challenges such as delivery methods and dosing regimens. Overall, the growing body of research underscores the promise of FGF-21 as a novel target in metabolic disease treatment, paving the way for potential advancements in clinical practice.
